Modified long-course radiation and chemo with immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer that is stage II or III and has not spread to other parts of your body.
- Your tumor is 'MSS' or 'pMMR' type, meaning it doesn't have a specific DNA repair problem.
- You have not had any previous treatment for your rectal cancer, like radiation, chemotherapy, or surgery.
- Your overall health is good, with adequate blood counts, kidney, liver, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (PD-1 inhibitor) for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes before surgery.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.